A clinical trial has shown that diagnostics company NanoLogix‘s (OTCBB: NNLX) rapid bacteria-detection test kits for Group B strep are, in fact, rapid.
The trial at the University of Texas Health Science Center found that the company’s technology detects Group B Streptococcus (GBS) within four to six hours of incubation, according to a statement from the Hubbard, Ohio-based company.
Current methods of detection take about 24 to 48 hours of incubation to obtain results, according to the American Pregnancy Association.
The trial results were published in the American Journal of Perinatology. “It’s the first true third-party, peer-reviewed valdation of our technology,” CEO Bret Barnhizer said. “To us, it’s huge.”
GBS is a bacterial infection that can be passed to a woman’s baby during delivery. The bacteria is normally found in the vagina and/or rectum of about 25 percent of all healthy adult women, the American Pregnancy Association said.
Click "source" for entire article.
"Rapid Diagnostic Test for Identifying Group B Streptococcus" (https://www.thieme-connect.com/ejournals/abstract/ajp/doi/10.1055/s-0031-1285099)